ArticleACS omega2025
3D-Printed Shellac-Based Delivery Systems: A Biopolymer Platform for Intestinal Targeting of Biologically Active Compounds.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Electrosprayed Shellac-Salt Nanoparticles for Improved Intestinal Dissolution and pH-Responsive Drug Release.ACS omega · 2026Article
- 3D-Printed Multifunctional Multicompartment Polymer-Based Capsules for Tunable and Spatially Controlled Drug Release.Journal of functional biomaterials · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents the development of 3D-printed shellac-based devices designed for site-specific intestinal delivery of bioactive compounds. The devices were fabricated using fused deposition modeling (FDM) 3D printing technology, employing a shellac filament plasticized with 20% w/w poly-(ethylene glycol) 10000 (PEG 10000). The influence of structural parametersspecifically base thickness (0.5-2 mm) and lateral wall thickness (1-2 mm)on mechanical performance, disintegration behavior, and release kinetics was systematically evaluated using propranolol hydrochloride as a model bioactive compound. Characterization via scanning electron microscopy (SEM), mechanical testing, and thermal analysis confirmed the successful fabrication of devices with a consistent morphology and robust mechanical properties. Increased thickness notably enhanced the mechanical strength and modulated the release profiles. Disintegration and dissolution testing demonstrated that thicker devices resisted acidic degradation while enabling timely release under simulated intestinal conditions. These results underscore the versatility of shellac-based 3D-printed platforms for precise, delayed, and site-specific intestinal releasenot only for pharmaceutical agents but also for sensitive macromolecules, probiotics, enzymes, and nutraceuticals requiring protection from gastric degradation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.